Richard Douglas

Track

Insider profile

Currently holds positions in Aldeyra Therapeutics Inc and Novavax Inc

Performance

Overall performance
3.6
Performance over holding periods
3.6
30 days 90 days 120 days
Average return 5% 8.2% 15.1%
Success rate 68% 68% 82%
Transactions
7 100% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Independent Chairman of the Board Aldeyra Therapeutics Inc Sept. 1, 2016 -
Independent Director Novavax Inc Aug. 6, 2010 -
Richard Douglas's trades of Aldeyra Therapeutics Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-03-20 2026-03-19
B Purchase
26,501 +39.7%
197.23
US$559,269 		26,501 +39.7% 197.23 US$559,269
2025-08-13 2025-08-13
US MaxCyte Inc (MXCT)
B Purchase
33,595 -48.5%
277.52
US$3,938,553 		33,595 -48.5% 277.52 US$3,938,553
2023-03-30 2023-03-29
US MaxCyte Inc (MXCT)
B Purchase
53,179
489.14
US$2,760,850 		53,179 489.14 US$2,760,850
2023-03-30 2023-03-29
US MaxCyte Inc (MXCT)
B Purchase
80,000 +400.0%
4.32
US$345,480 		80,000 +400.0% 4.32 US$345,480
2021-11-23 2021-11-22
US MaxCyte Inc (MXCT)
B Purchase
20,000 +inf%
11.12
US$222,400 		20,000 +inf% 11.12 US$222,400
2020-03-17 2020-03-16
B Purchase
40,000 +47.1%
2.75
US$110,000 		40,000 +47.1% 2.75 US$110,000
2019-09-17 2019-09-13
B Purchase
5,000 +6.2%
6.00
US$30,000 		5,000 +6.2% 6.00 US$30,000
2019-09-13 2019-09-12
B Purchase
10,000 +14.3%
6.03
US$60,276 		10,000 +14.3% 6.03 US$60,276
2019-09-13 2019-09-11
B Purchase
10,000 +16.7%
5.75
US$57,529 		10,000 +16.7% 5.75 US$57,529
2019-09-11 2019-09-10
B Purchase
10,000 +20.0%
5.09
US$50,857 		10,000 +20.0% 5.09 US$50,857
2019-09-11 2019-09-09
B Purchase
10,000 +25.0%
4.91
US$49,106 		10,000 +25.0% 4.91 US$49,106